Fundraising Fox
CamGene Therapeutics
Cambridge, GB · 4 known investors
Find your way into CamGene Therapeutics
305 people in our graph share verified history with the CamGene Therapeutics team — schools, employers, funds. One of them is your warm intro.
Oliver Sextonunlockedknows Arpan Desai · together at CamGene Therapeutics (overlapped)
knows the team · via CamGene Therapeutics
×10knows the team · via AstraZeneca
CamGene Therapeutics develops RNA-based medicines, including mRNA, siRNA, and antisense oligonucleotides delivered via lipid nanoparticles, to treat the underlying cellular dysfunction that causes hearing loss. The company aims to modulate protein expression for regeneration and protection of cells in the cochlea as an accessible mass-market therapeutic.
Founders & leadership
AD
Arpan DesaiCEO & Co-founderArpan Desai leads pharmaceutical R&D teams focused on nucleic acid-based therapeutics and is Co-founder and CEO of CamGene Therapeutics, which develops RNA medicines to treat hearing loss.
PS
Prashant ShahCo-founder
SS
Sunil ShahCo-founder
Investors · 4
Eos Advisorylisted by Eos AdvisorySt Andrews
How we know: the VCSheet dataset · Not right? Tell us
Companies House · registry record
View on Companies House ↗Confirmation statement overdue
- Registered name
- CAMGENE THERAPEUTICS LIMITED
- Company number
- 14921810
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Jun 2023
- Registered office
- Hauxton House Mill Scitech Park Mill Lane, Hauxton, Cambridge, CB22 5HX
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 30 Sept 2025 · next due 30 Jun 2027
- Confirmation statement
- last made up to 6 Jun 2025 · next due 20 Jun 2026
Current officers · 6
- Manohar Lal Bance — director, appointed 23 Sept 2024
- John William Beadle — director, appointed 4 Nov 2025
- Arpan Desai — director, appointed 7 Jun 2023
- Barbara Pauline Domayne-Hayman — director, appointed 4 Nov 2025
- Peter Oliver Wharton Sexton — director, appointed 29 Sept 2025
- Timothy Jason Sparey — director, appointed 5 Nov 2025
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does CamGene Therapeutics do?
- CamGene Therapeutics develops RNA-based medicines, including mRNA, siRNA, and antisense oligonucleotides delivered via lipid nanoparticles, to treat the underlying cellular dysfunction that causes hearing loss. The company aims to modulate protein expression for regeneration and protection of cells in the cochlea as an accessible mass-market therapeutic.
- Who founded CamGene Therapeutics?
- CamGene Therapeutics was founded by Arpan Desai, Prashant Shah, Sunil Shah.
- Who are CamGene Therapeutics's investors?
- CamGene Therapeutics's investors include Cambridge Angels group, Eos Advisory, Future Planet Capital, UK Innovation & Science Seed Fund.
- Where is CamGene Therapeutics headquartered?
- CamGene Therapeutics is headquartered in Cambridge, GB.